JP2007505938A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007505938A5 JP2007505938A5 JP2006527348A JP2006527348A JP2007505938A5 JP 2007505938 A5 JP2007505938 A5 JP 2007505938A5 JP 2006527348 A JP2006527348 A JP 2006527348A JP 2006527348 A JP2006527348 A JP 2006527348A JP 2007505938 A5 JP2007505938 A5 JP 2007505938A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- inhibitors
- kinase
- vegf
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002401 inhibitory effect Effects 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims 19
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 229940112871 Bisphosphonate drugs affecting bone structure and mineralization Drugs 0.000 claims 3
- 102100013180 KDR Human genes 0.000 claims 3
- 210000004688 Microtubules Anatomy 0.000 claims 3
- 102000028664 Microtubules Human genes 0.000 claims 3
- 108091022031 Microtubules Proteins 0.000 claims 3
- 108091007928 VEGF receptors Proteins 0.000 claims 3
- 102100015249 VEGFA Human genes 0.000 claims 3
- YCOYDOIWSSHVCK-UHFFFAOYSA-N Vatalanib Chemical group C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 3
- 239000012190 activator Substances 0.000 claims 3
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 239000003886 aromatase inhibitor Substances 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- 150000004663 bisphosphonates Chemical class 0.000 claims 3
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 3
- 229960000060 monoclonal antibodies Drugs 0.000 claims 3
- 102000005614 monoclonal antibodies Human genes 0.000 claims 3
- 108010045030 monoclonal antibodies Proteins 0.000 claims 3
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 3
- 102100011141 ALK Human genes 0.000 claims 2
- 102000001301 EGF receptors Human genes 0.000 claims 2
- 108060006698 EGF receptors Proteins 0.000 claims 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 claims 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 claims 2
- 108091007929 PDGF receptors Proteins 0.000 claims 2
- 102000029987 Phosphatidylethanolamine-binding protein Human genes 0.000 claims 2
- 108091000043 Phosphatidylethanolamine-binding protein Proteins 0.000 claims 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- WKPUACLQLIIVJJ-RHKLHVFKSA-M (2S,3R,4R,5S,6R)-4-hydroxy-3-methoxy-6-[(2S,3R,4S,5S,6R)-6-methoxy-4-oxido-5-(sulfooxyamino)-2-(sulfooxymethyl)oxan-3-yl]oxy-5-sulfooxyoxane-2-carboxylate Chemical compound [O-][C@H]1[C@H](NOS(O)(=O)=O)[C@H](OC)O[C@@H](COS(O)(=O)=O)[C@@H]1O[C@H]1[C@@H](OS(O)(=O)=O)[C@H](O)[C@@H](OC)[C@@H](C([O-])=O)O1 WKPUACLQLIIVJJ-RHKLHVFKSA-M 0.000 claims 1
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 claims 1
- 229940030495 ANTIANDROGEN SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM Drugs 0.000 claims 1
- 102000005758 Adenosylmethionine Decarboxylase Human genes 0.000 claims 1
- 108010070753 Adenosylmethionine Decarboxylase Proteins 0.000 claims 1
- 229940046836 Anti-estrogens Drugs 0.000 claims 1
- 108060001001 BRK1 Proteins 0.000 claims 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N Bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 210000003679 Cervix Uteri Anatomy 0.000 claims 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 claims 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 claims 1
- 102100003684 HPSE Human genes 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 229920002971 Heparan sulfate Polymers 0.000 claims 1
- 102100011311 KNG1 Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 101710039852 METAP1 Proteins 0.000 claims 1
- 101710012506 METAP2 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 108091000081 Phosphotransferases Proteins 0.000 claims 1
- 210000002307 Prostate Anatomy 0.000 claims 1
- 102000001253 Protein Kinases Human genes 0.000 claims 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 claims 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 claims 1
- 102000011096 Somatostatin receptor family Human genes 0.000 claims 1
- 108050001286 Somatostatin receptor family Proteins 0.000 claims 1
- 210000002784 Stomach Anatomy 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 210000003932 Urinary Bladder Anatomy 0.000 claims 1
- 210000004291 Uterus Anatomy 0.000 claims 1
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 claims 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000002280 anti-androgenic Effects 0.000 claims 1
- 230000001772 anti-angiogenic Effects 0.000 claims 1
- 230000002424 anti-apoptotic Effects 0.000 claims 1
- 230000001833 anti-estrogenic Effects 0.000 claims 1
- 230000000719 anti-leukaemic Effects 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 claims 1
- 229940045985 antineoplastic drugs Platinum compounds Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000711 cancerogenic Effects 0.000 claims 1
- 231100000315 carcinogenic Toxicity 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 230000001472 cytotoxic Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 239000003954 decarboxylase inhibitor Substances 0.000 claims 1
- 230000004059 degradation Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 239000000328 estrogen antagonist Substances 0.000 claims 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 1
- 229960001442 gonadorelin Drugs 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 108010037536 heparanase Proteins 0.000 claims 1
- 239000000367 immunologic factor Substances 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims 1
- 229940121386 matrix metalloproteinase inhibitors Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000003277 telomerase inhibitor Substances 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 claims 1
- 238000010798 ubiquitination Methods 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 239000000203 mixture Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 2
- -1 methoxy, ethoxy, isopropyloxy Chemical group 0.000 description 2
- 125000006610 n-decyloxy group Chemical group 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
Description
組み合わせパートナー(ａ)および(ｂ)は、一緒に、交互にまたは別々に、一つの組み合わされた投与単位形でまたは２個の別々の単位投与形で投与できる。単位投与形はまた固定された組み合わせであり得る。
エーテル化ヒドロキシは、とりわけＣ８−２０アルキルオキシ、例えばｎ−デシルオキシ；低級アルコキシ(好ましい)、例えばメトキシ、エトキシ、イソプロピルオキシまたはｎ−ペンチルオキシ；フェニル−低級アルコキシ、例えばベンジルオキシ；またはフェニルオキシでもあり、または前記の群に加えて、またはそれとは別にＣ８−２０アルキルオキシ、例えばｎ−デシルオキシ；ハロゲン−低級アルコキシ、例えばトリフルオロメチルオキシまたは１,１,２,２−テトラフルオロエトキシである。
式(III)中の環員Ａ、Ｂ、ＤおよびＥの中で、Ｎは２個を超えず、残りのものはＣＨである。好ましくは、環員Ａ、Ｂ、ＤおよびＥの各々がＣＨである。
本発明の医薬組成物は、慣用の手段で製造でき、ヒトを含む哺乳類への経腸、例えば経口または直腸、および、非経腸投与に適しているものであり、治療的有効量のＶＥＧＦ阻害剤と、少なくとも１個の治療剤を、単独で、または１個またはそれ以上の薬学的に許容される担体、とりわけ経腸または非経腸適用に適したものと組み合わせて含む。
Claims (4)
- (ａ)１−(４−クロロアニリノ)−４−(４−ピリジルメチル)フタラジンまたはその薬学的に許容される塩であるＶＥＧＦ阻害剤；および
(ｂ)下記から成る群から選択される１種またはそれ以上の化学療法剤：
ｉ. アロマターゼ阻害剤；
ii. 抗エストロゲン、抗アンドロゲンまたはゴナドレリンアゴニスト；
iii. トポイソメラーゼＩ阻害剤またはトポイソメラーゼII阻害剤；
iv. 微小管活性化剤、アルキル化剤、抗新生物代謝拮抗剤または白金化合物；
ｖ. タンパク質または脂質キナーゼ活性またはタンパク質または脂質ホスファターゼ活性を標的／減少する化合物、さらに抗血管形成化合物または細胞分化過程を誘発する化合物；
vi. ブラジキニン１受容体またはアンギオテンシンIIアンタゴニスト；
vii. シクロオキシゲナーゼ阻害剤、ビスホスホネート、ヘパラナーゼ阻害剤(ヘパラン硫酸分解を防止)、生物学的応答修飾剤、ユビキチン化阻害剤、または抗アポトーシス経路を遮断する阻害剤；
viii. Ｒａｓ発癌性イソ型の阻害剤またはファルネシルトランスフェラーゼ阻害剤；
ix. テロメラーゼ阻害剤；
ｘ. プロテアーゼ阻害剤、マトリックスメタロプロテイナーゼ阻害剤、メチオニンアミノペプチダーゼ阻害剤、またはプロテオソーム阻害剤；
xi. 血液学的悪性物の処置に使用する薬剤またはＦＭＳ様チロシンキナーゼ阻害剤；
xii. ＨＳＰ９０阻害剤；
xiii. ＨＤＡＣ阻害剤；
xiv. ｍＴＯＲ阻害剤；
xv. ソマトスタチン受容体アンタゴニスト；
xvi. インテグリンアンタゴニスト；
xvii. 抗白血病性化合物；
xviii. 電離放射線のような腫瘍細胞傷害法；
xix. ＥＤＧ結合剤；
xx. アントラニル酸アミドクラスのキナーゼ阻害剤；
xxi. リボヌクレオチドレダクターゼ阻害剤；
xxii. Ｓ−アデノシルメチオニンデカルボキシラーゼ阻害剤；
xxiii. ＶＥＧＦまたはＶＥＧＦＲのモノクローナル抗体；
xxiv. 光線力学的治療；
xxv. 血管新生抑制性ステロイド；
xxvi. コルチコステロイド含有インプラント；
xxvii. ＡＴ１受容体アンタゴニスト；および
xxviii. ＡＣＥ阻害剤
を含む、医薬組成物。 - (ａ)１−(４−クロロアニリノ)−４−(４−ピリジルメチル)フタラジンまたはその薬学的に許容される塩であるＶＥＧＦ阻害剤；および
(ｂ)ＨＤＡＣ阻害剤、微小管活性剤、ＥＧＦ受容体チロシンキナーゼファミリーの阻害剤、ｍＴＯＲ阻害剤、ＣＯＸ−２阻害剤、電離放射線、ＩＧＦ−ＩＲ阻害剤、アロマターゼ阻害剤、ビスホスホネート、Ｂｃｒ−Ａｂｌキナーゼ阻害剤、ＦＬＴ−３Ｒキナーゼ阻害剤、ＡＬＫ阻害剤、ｃ−Ｋｉｔ阻害剤、血小板由来増殖因子受容体阻害剤、Ｒａｆキナーゼ阻害剤、ＨＳＰ−９０阻害剤、ＶＥＧＦおよびＶＥＧＦＲのモノクローナル抗体、ＭＭＰ阻害剤、ＳＲＣ阻害剤、ファルネシルトランスフェラーゼ阻害剤およびＥＤＧ結合剤から成る群から選択される１種またはそれ以上の化学療法剤
を含む、請求項１記載の医薬組成物。 - (ａ)１−(４−クロロアニリノ)−４−(４−ピリジルメチル)フタラジンまたはその薬学的に許容される塩であるＶＥＧＦ阻害剤；および
(ｂ)ＨＤＡＣ阻害剤、微小管活性剤、ＥＧＦ受容体チロシンキナーゼファミリーの阻害剤、ｍＴＯＲ阻害剤、ＣＯＸ−２阻害剤、電離放射線、ＩＧＦ−ＩＲ阻害剤、アロマターゼ阻害剤、ビスホスホネート、Ｂｃｒ−Ａｂｌキナーゼ阻害剤、ＦＬＴ−３Ｒキナーゼ阻害剤、ＡＬＫ阻害剤、ｃ−Ｋｉｔ阻害剤、血小板由来増殖因子受容体阻害剤、Ｒａｆキナーゼ阻害剤、ＨＳＰ−９０阻害剤、ＶＥＧＦおよびＶＥＧＦＲのモノクローナル抗体、ＭＭＰ阻害剤、ＳＲＣ阻害剤、ファルネシルトランスフェラーゼ阻害剤およびＥＤＧ結合剤から成る群から選択される１種またはそれ以上の化学療法剤
を含む、請求項１記載の医薬組成物。 - 乳癌、肺癌、卵巣癌、リンパ腫、頭頚部癌または食道、胃、膀胱、前立腺、子宮もしくは頸の癌を予防または処置するための、請求項１から３のいずれかに記載の医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50525003P | 2003-09-23 | 2003-09-23 | |
| PCT/EP2004/010686 WO2005027972A2 (en) | 2003-09-23 | 2004-09-23 | Combination of a vegf receptor inhibitor with a chemotherapeutic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007505938A JP2007505938A (ja) | 2007-03-15 |
| JP2007505938A5 true JP2007505938A5 (ja) | 2007-11-08 |
Family
ID=34375569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006527348A Pending JP2007505938A (ja) | 2003-09-23 | 2004-09-23 | Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080085902A1 (ja) |
| EP (1) | EP1682181A2 (ja) |
| JP (1) | JP2007505938A (ja) |
| KR (1) | KR20060097000A (ja) |
| CN (1) | CN1856327A (ja) |
| AU (1) | AU2004273615B2 (ja) |
| BR (1) | BRPI0414698A (ja) |
| CA (1) | CA2537991A1 (ja) |
| CO (1) | CO5680459A2 (ja) |
| CR (1) | CR8283A (ja) |
| EA (1) | EA200600495A1 (ja) |
| EC (1) | ECSP066437A (ja) |
| IL (1) | IL174214A0 (ja) |
| MX (1) | MXPA06003163A (ja) |
| NO (1) | NO20061777L (ja) |
| WO (1) | WO2005027972A2 (ja) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
| US7399480B2 (en) | 1997-09-26 | 2008-07-15 | Abbott Laboratories | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
| EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
| AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| EP3581228A1 (en) * | 2003-02-21 | 2019-12-18 | ResMed Pty Ltd | Nasal assembly for delivering breathable gas to a patient |
| US7994159B2 (en) | 2003-03-10 | 2011-08-09 | Eisai R&D Management Co., Ltd. | c-Kit kinase inhibitor |
| JP4860474B2 (ja) | 2003-05-20 | 2012-01-25 | バイエル、ファーマシューテイカルズ、コーポレイション | Ｐｄｇｆｒによって仲介される病気のためのジアリール尿素 |
| DK1663978T3 (da) | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
| JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
| WO2005070020A2 (en) | 2004-01-23 | 2005-08-04 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
| CA2564868C (en) * | 2004-04-28 | 2013-11-26 | Molecules For Health, Inc. | Methods for treating or preventing restenosis and other vascular proliferative disorders |
| ES2677562T3 (es) | 2004-05-27 | 2018-08-03 | The Regents Of The University Of Colorado | Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer |
| JP4834553B2 (ja) | 2004-09-17 | 2011-12-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
| EP1796672A1 (en) * | 2004-09-27 | 2007-06-20 | AstraZeneca AB | Cancer combination therapy comprising azd2171 and imatinib |
| JP4954083B2 (ja) | 2004-11-18 | 2012-06-13 | シンタ ファーマスーティカルズ コーポレイション | Ｈｓｐ９０活性を調節するトリアゾール化合物 |
| US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| PL3248600T3 (pl) | 2005-02-18 | 2020-09-07 | Abraxis Bioscience, Llc | Połączenia i sposoby podawania środków terapeutycznych i terapia skojarzona |
| UA93673C2 (ru) * | 2005-03-07 | 2011-03-10 | Баер Шеринг Фарма Акциенгезельшафт | Фармацевтическая композиция, которая содержит омега-карбоксиарилзамещенную дифенилмочевину, для лечения paka |
| JP2009502960A (ja) * | 2005-07-27 | 2009-01-29 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| EP1942882A2 (en) * | 2005-10-24 | 2008-07-16 | Novartis AG | Combination of histone deacetylase inhibitors and radiation |
| CA2627598C (en) * | 2005-11-07 | 2013-06-25 | Eisai R & D Management Co., Ltd. | Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| CN100441222C (zh) * | 2005-12-09 | 2008-12-10 | 中国科学院广州生物医药与健康研究院 | 化合物ps-341在制备治疗急性髓性白血病药物中的应用 |
| FR2895258B1 (fr) * | 2005-12-22 | 2008-03-21 | Aventis Pharma Sa | Combinaison comprenant de la combretastatine et des agents anticancereux |
| US20070258976A1 (en) * | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
| JP5190361B2 (ja) | 2006-05-18 | 2013-04-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 甲状腺癌に対する抗腫瘍剤 |
| KR20090015968A (ko) | 2006-06-12 | 2009-02-12 | 노파르티스 아게 | Ｎ-히드록시-3-[4-[[[2-(2-메틸-1ｈ-인돌-3-일)에틸]아미노]메틸]페닐]-2ｅ-2-프로펜아미드의 동질이상체 |
| US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
| WO2008033746A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| AU2008211952B2 (en) | 2007-01-29 | 2012-07-19 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
| EP2030615A3 (en) | 2007-08-13 | 2009-12-02 | ELFORD, Howard L. | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases |
| WO2009036066A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| EP2060565A1 (en) * | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| EP2278966B1 (en) | 2008-03-21 | 2019-10-09 | The University of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| JP5425180B2 (ja) | 2008-03-27 | 2014-02-26 | ザイモジェネティクス， インコーポレイテッド | ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法 |
| EP2393513B1 (en) | 2009-02-06 | 2016-10-19 | The General Hospital Corporation | Methods of treating vascular lesions |
| WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
| AR077975A1 (es) | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| KR101431348B1 (ko) * | 2009-09-30 | 2014-08-19 | 가부시키가이샤 시세이도 | 헤파라나제 활성 저해제 |
| KR20120129904A (ko) | 2010-01-14 | 2012-11-28 | 공립대학법인 나고야 시립대학 | 안내 혈관 신생 및/또는 안내 혈관 투과성 항진을 수반하는 질환의 예방 또는 치료를 위한 의약 |
| NZ628423A (en) | 2010-03-29 | 2016-03-31 | Abraxis Bioscience Llc | Methods of treating cancer |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| SG186112A1 (en) | 2010-06-04 | 2013-01-30 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
| CA2802644C (en) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| EP2671589A4 (en) | 2011-02-02 | 2014-11-19 | Public Univ Corp Nagoya City Univ | MEDICINAL AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH INTRAOCULAR NEOVASCULARIZATION AND / OR INTRAOCULAR VASCULAR HYPERPERMABILITY |
| CA2828946C (en) | 2011-04-18 | 2016-06-21 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| US20140286902A1 (en) | 2011-11-02 | 2014-09-25 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
| JP2014532712A (ja) | 2011-11-02 | 2014-12-08 | シンタ ファーマシューティカルズ コーポレーション | トポイソメラーゼｉ阻害剤とｈｓｐ９０阻害剤の組合せを使用する癌療法 |
| CA2855243C (en) | 2011-11-11 | 2020-04-14 | Novartis Ag | Method of treating a proliferative disease |
| EP2780010A1 (en) | 2011-11-14 | 2014-09-24 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| US20150283136A1 (en) * | 2012-11-08 | 2015-10-08 | Novartis Ag | Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases |
| WO2014098176A1 (ja) | 2012-12-21 | 2014-06-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
| KR102204279B1 (ko) | 2013-05-14 | 2021-01-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 자궁내막암 대상의 렌바티닙 화합물에 대한 반응성을 예측 및 평가하기 위한 생체표지 |
| JP2017520603A (ja) * | 2014-07-14 | 2017-07-27 | シグナル ファーマシューティカルズ，エルエルシー | 置換ピロロピリミジン化合物を使用するがんの治療方法及びその組成物 |
| MX2017001980A (es) | 2014-08-28 | 2017-05-04 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y metodo para su produccion. |
| BR102014023144B1 (pt) * | 2014-09-18 | 2020-12-15 | Universidade De São Paulo - Usp | peptídeos sintéticos ligantes de receptores de vegf e seus usos |
| BR112017017428A2 (ja) | 2015-02-25 | 2018-04-03 | Eisai R&D Management Co., Ltd. | A bitter taste inhibition method of a quinoline derivative |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| JP6757959B2 (ja) | 2015-06-16 | 2020-09-23 | 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ | 抗がん剤 |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2020245208A1 (en) | 2019-06-04 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| KR102371269B1 (ko) * | 2020-03-11 | 2022-03-07 | 연세대학교 산학협력단 | VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| PE20020354A1 (es) * | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| WO2002066479A1 (fr) * | 2001-02-23 | 2002-08-29 | Banyu Pharmaceutical Co.,Ltd. | Derives de l'isoindole |
| BR0212446A (pt) * | 2001-09-12 | 2004-08-17 | Novartis Ag | Uso de 4-piridilmetilftalazinas para tratamento de câncer |
| IL161462A0 (en) * | 2001-10-25 | 2004-09-27 | Novartis Ag | Combinations comprising a selective cyclooxygenase-2 inhibitor |
| CN1849122A (zh) * | 2001-12-03 | 2006-10-18 | 先灵公司 | Fpt抑制剂与至少两种抗肿瘤药在治疗癌症中的用途 |
-
2004
- 2004-09-23 WO PCT/EP2004/010686 patent/WO2005027972A2/en active Application Filing
- 2004-09-23 CA CA002537991A patent/CA2537991A1/en not_active Abandoned
- 2004-09-23 JP JP2006527348A patent/JP2007505938A/ja active Pending
- 2004-09-23 KR KR1020067005644A patent/KR20060097000A/ko not_active Application Discontinuation
- 2004-09-23 MX MXPA06003163A patent/MXPA06003163A/es not_active Application Discontinuation
- 2004-09-23 EA EA200600495A patent/EA200600495A1/ru unknown
- 2004-09-23 US US10/573,163 patent/US20080085902A1/en not_active Abandoned
- 2004-09-23 AU AU2004273615A patent/AU2004273615B2/en not_active Ceased
- 2004-09-23 CN CNA2004800275441A patent/CN1856327A/zh active Pending
- 2004-09-23 BR BRPI0414698-0A patent/BRPI0414698A/pt not_active IP Right Cessation
- 2004-09-23 EP EP04765542A patent/EP1682181A2/en not_active Withdrawn
-
2006
- 2006-03-09 IL IL174214A patent/IL174214A0/en unknown
- 2006-03-14 CR CR8283A patent/CR8283A/es not_active Application Discontinuation
- 2006-03-17 EC EC2006006437A patent/ECSP066437A/es unknown
- 2006-03-30 CO CO06031465A patent/CO5680459A2/es not_active Application Discontinuation
- 2006-04-21 NO NO20061777A patent/NO20061777L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007505938A5 (ja) | ||
| Eckhardt | Recent progress in the development of anticancer agents | |
| US20230133044A1 (en) | Therapeutic benefit of suboptimally administered chemical compounds | |
| JP2020079259A (ja) | 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法 | |
| KR102462177B1 (ko) | Ｍｄｍ２ 억제제의 간헐적 투여 | |
| Woyach et al. | New therapeutic advances in the management of progressive thyroid cancer | |
| EA200600495A1 (ru) | Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом | |
| JP2020172504A (ja) | チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用 | |
| RU2002129000A (ru) | Синергические способы и композиции для лечения рака | |
| EP1492567A1 (en) | Formulations and methods of using nitric oxide mimetics in cancer treatment | |
| Ory et al. | Blocking HSP90 addiction inhibits tumor cell proliferation, metastasis development, and synergistically acts with zoledronic acid to delay osteosarcoma progression | |
| WO2009002553A1 (en) | Methods of treating multiple myeloma and resistant cancers | |
| US20190358229A1 (en) | Pac-1 combination therapy | |
| JP6526789B2 (ja) | 組み合わせ療法 | |
| MXPA05009708A (es) | Metodo para el tratamiento de cancer con composiciones de azaspirina. | |
| CN1889952A (zh) | (a)N－{5－[4－(4－甲基－(哌嗪－1－基)－甲基)－苯甲酰胺基]－2－甲基苯基}－4－(3－吡啶基)－2－嘧啶－胺和( b )至少一种羟丁赖氨酸形成抑制剂的组合产品及其用途 | |
| JP2022547702A (ja) | 胆管癌の処置のためのパノビノスタットを含む併用療法 | |
| US11850234B2 (en) | Enhancement of cancer treatment efficiency via the sphingosine-1-phosphate pathway | |
| WO2022127751A1 (zh) | 医药组合物治疗肺癌的用途 | |
| RU2776995C2 (ru) | Виды комбинированной лекарственной терапии с использованием лекарственных препаратов, целенаправленно воздействующих на костную ткань, для лечения костей и заболевания, связанного с костной тканью | |
| US20060167006A1 (en) | Method of treatment | |
| JP2024523861A (ja) | がんを処置するための併用療法におけるｅｇｆｒ阻害剤およびｐｅｒｋ活性化剤、ならびにこれらの使用 | |
| Linkous et al. | New Molecular Targets for Anti-Angiogenic Therapeutic Strategies |